Compare OZ & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | ABEO |
|---|---|---|
| Founded | 2020 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 280.2M |
| IPO Year | 2020 | 2005 |
| Metric | OZ | ABEO |
|---|---|---|
| Price | $52.34 | $4.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.75 |
| AVG Volume (30 Days) | 11.5K | ★ 978.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.74 |
| EPS | N/A | ★ 1.35 |
| Revenue | $2,675,000.00 | ★ $2,998,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | ★ N/A | $3.71 |
| Revenue Growth | 18.68 | ★ 258.18 |
| 52 Week Low | $48.50 | $3.93 |
| 52 Week High | $75.73 | $7.54 |
| Indicator | OZ | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 43.97 |
| Support Level | $52.02 | $4.87 |
| Resistance Level | $64.85 | $5.60 |
| Average True Range (ATR) | 1.05 | 0.20 |
| MACD | 0.48 | -0.01 |
| Stochastic Oscillator | 85.13 | 22.97 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.